Control of Klebsiella pneumoniae pulmonary infection and immunomodulation by oral treatment with the commensal probiotic Bifidobacterium longum 51A

Microbes and Infection

Volumn 18, Issue 3, 2016, Pages 180-189

  Vieira, Angélica T ^a   Rocha, Victor M ^a   Tavares, Luciana ^a   Garcia, Cristiana C ^b   Teixeira, Mauro M ^a   Oliveira, Sérgio C ^a   Cassali, Geovanni D ^a   Gamba, Conrado ^a   Martins, Flaviano S ^a   Nicoli, Jacques R ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Bifidobacterium longum 51A; Inflammation; Klebsiella pneumoniae; Mal TIRAP; Microbiota; Probiotic

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; PROBIOTIC AGENT; PROTEIN MAL; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL LOAD; BIFIDOBACTERIUM LONGUM; COMMENSAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; HOST RESISTANCE; IMMUNITY; IMMUNOMODULATION; IMMUNOREGULATION; INFECTION CONTROL; INFECTION PREVENTION; INFECTION SENSITIVITY; INFLAMMATION; INFLAMMATORY CELL; KLEBSIELLA PNEUMONIAE INFECTION; LETHALITY; LUNG ALVEOLUS MACROPHAGE; LUNG INFECTION; LUNG INJURY; LUNG LAVAGE; MONONUCLEAR CELL; MOUSE; NEUTROPHIL; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYSTEMIC CIRCULATION; ANIMAL; BIFIDOBACTERIUM; C57BL MOUSE; CHILD; DISEASE MODEL; HUMAN; IMMUNOLOGY; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; PNEUMONIA, BACTERIAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANIMALS; BACTERIAL LOAD; BIFIDOBACTERIUM; CHILD; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOMODULATION; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE, INBRED C57BL; PNEUMONIA, BACTERIAL; PROBIOTICS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84960853258     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2015.10.008     Document Type: Article

References (51)

1. Mizgerd J.P. Lung infection-a public health priority. PLoS Med 2006, 3:e76.
2. Armstrong G.L., Conn L.A., Pinner R.W. Trends in infectious disease mortality in the United States during the 20th century. JAMA 1999, 281:61-66.
3. Soares A.C., Souza D.G., Pinho V., Vieira A.T., Nicoli J.R., Cunha F.Q., et al. Dual function of the long pentraxin PTX3 in resistance against pulmonary infection with Klebsiella pneumoniae in transgenic mice. Microbes Infect 2006, 8:1321-1329.
4. Zhang P., Summer W.R., Bagby G.J., Nelson S. Innate immunity and pulmonary host defense. Immunol Rev 2000, 173:39-51.
5. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008, 454:428-435.
6. Reid G., Jass J., Sebulsky M.T., McCormick J.K. Potential uses of probiotics in clinical practice. Clin Microbiol Rev 2003, 16:658-672.
7. Vieira A.T., Teixeira M.M., Martins F.S. The role of probiotics and prebiotics in inducing gut immunity. Front Immunol 2013, 4:445.
8. Fagundes C.T., Amaral F.A., Vieira A.T., Soares A.C., Pinho V., Nicoli J.R., et al. Transient TLR activation restores inflammatory response and ability to control pulmonary bacterial infection in germfree mice. J Immunol 2012, 188:1411-1420.
9. Kawase M., He F., Kubota A., Harata G., Hiramatsu M. Oral administration of lactobacilli from human intestinal tract protects mice against influenza virus infection. Lett Appl Microbiol 2010, 51:6-10.
10. Kawahara T., Takahashi T., Oishi K., Tanaka H., Masuda M., Takahashi S., et al. Consecutive oral administration of bifidobacterium longum MM-2 improves the defense system against influenza virus infection by enhancing natural killer cell activity in a murine model. Microbiol Immunol 2015, 59:1-12.
11. Song J.A., Kim H.J., Hong S.K., Lee D.H., Lee S.W., Song C.S., et al. Oral intake of Lactobacillus rhamnosus M21 enhances the survival rate of mice lethally infected with influenza virus. J Microbiol Immunol Infect 2014, xx:1-8. 10.1016/j.jmii.2014.07.011.
12. Souza T.C., Silva A.M., Drews J.R., Gomes D.A., Vinderola C.G., Nicoli J.R. In vitro evaluation of bifidobacterium strains of human origin for potential use in probiotic functional foods. Benef Microbes 2013, 4:179-186.
13. Souza T.C., Zacarias M.F., Silva A.M., Binetti A., Reinheimer J., Nicoli J.R., et al. Cell viability and immunostimulating and protective capacities of bifidobacterium longum 51A are differentially affected by technological variables in fermented milks. J Appl Microbiol 2012, 112:1184-1192.
14. Guerra P.V., Lima L.N., Souza T.C., Mazochi V., Penna F.J., Silva A.M., et al. Pediatric functional constipation treatment with bifidobacterium-containing yogurt: a crossover, double-blind, controlled trial. World J Gastroenterol 2011, 17:3916-3921.
15. Vieira A, GI T, Amaral FA, Nicoli JR, Teixeira MM, Martins FS. Oral treatment with bifidobacterium longum 51A reduced inflammation 4 in a murine experimental model of gout beneficial of Microbes 2015. [ahead of print].
16. Vieira A.T., Macia L., Galvao I., Martins F.S., Canesso M.C., Amaral F.A., et al. A role for gut microbiota and the metabolite-sensing receptor GPR43 in a murine model of gout. Arthritis Rheumatol 2015, 67:1646-1656.
17. Forman H.J., Torres M. Reactive oxygen species and cell signaling: respiratory burst in macrophage signaling. Am J Respir Crit Care Med 2002, 166:S4-S8.
18. Rosenberger C.M., Finlay B.B. Phagocyte sabotage: disruption of macrophage signalling by bacterial pathogens. Nat Rev Mol Cell Biol 2003, 4:385-396.
19. Bernard N.J., O'Neill L.A. Mal, more than a bridge to MyD88. IUBMB Life 2013, 65:777-786.
20. Jeyaseelan S., Young S.K., Yamamoto M., Arndt P.G., Akira S., Kolls J.K., et al. Toll/IL-1R domain-containing adaptor protein (TIRAP) is a critical mediator of antibacterial defense in the lung against Klebsiella pneumoniae but not Pseudomonas aeruginosa. J Immunol 2006, 177:538-547.
21. Cai S., Batra S., Lira S.A., Kolls J.K., Jeyaseelan S. CXCL1 regulates pulmonary host defense to Klebsiella infection via CXCL2, CXCL5, NF-kappaB, and MAPKs. J Immunol 2010, 185:6214-6225.
22. Craig A., Mai J., Cai S., Jeyaseelan S. Neutrophil recruitment to the lungs during bacterial pneumonia. Infect Immun 2009, 77:568-575.
23. Forsythe P. Probiotics and lung immune responses. Ann Am Thorac Soc 2014, 11(Suppl. 1):S33-S37.
24. Verheijden K.A., Willemsen L.E., Braber S., Leusink-Muis T., Jeurink P.V., Garssen J., et al. The development of allergic inflammation in a murine house dust mite asthma model is suppressed by synbiotic mixtures of non-digestible oligosaccharides and bifidobacterium breve M-16V. Eur J Nutr 2015, 54:1-11. 10.1007/s00394-015-0928-8.
25. Drago L., De Vecchi E., Gabrieli A., De Grandi R., Toscano M. Immunomodulatory effects of Lactobacillus salivarius LS01 and bifidobacterium breve BR03, alone and in combination, on peripheral blood mononuclear cells of allergic asthmatics. Allergy Asthma Immunol Res 2015, 7:409-413.
26. Kim Y.G., Udayanga K.G., Totsuka N., Weinberg J.B., Nunez G., Shibuya A. Gut dysbiosis promotes M2 macrophage polarization and allergic airway inflammation via fungi-induced PGE(2). Cell Host Microbe 2014, 15:95-102.
27. Russell S.L., Gold M.J., Hartmann M., Willing B.P., Thorson L., Wlodarska M., et al. Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. EMBO Rep 2012, 13:440-447.
28. Thorburn A.N., Macia L., Mackay C.R. Diet, metabolites, and "western-lifestyle" inflammatory diseases. Immunity 2014, 40:833-842.
29. Trompette A., Gollwitzer E.S., Yadava K., Sichelstiel A.K., Sprenger N., Ngom-Bru C., et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med 2014, 20:159-166.
30. Fukuda S., Toh H., Hase K., Oshima K., Nakanishi Y., Yoshimura K., et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 2011, 469:543-547.
31. Arpaia N., Campbell C., Fan X., Dikiy S., van der Veeken J., deRoos P., et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013, 504:451-455.
32. Maslowski K.M., Vieira A.T., Ng A., Kranich J., Sierro F., Yu D., et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009, 461:1282-1286.
33. Vinolo M.A., Rodrigues H.G., Hatanaka E., Sato F.T., Sampaio S.C., Curi R. Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. J Nutr Biochem 2011, 22:849-855.
34. Lenz A.M., Franklin G.A., Fairweather M., McClintock M.L., Jala V.R., Peyton J.C., et al. Endogenous IL-10 leads to impaired bacterial clearance and reduced survival in a murine model of chronic peritonitis. Cytokine 2007, 40:207-215.
35. Greenberger M.J., Strieter R.M., Kunkel S.L., Danforth J.M., Goodman R.E., Standiford T.J. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 1995, 155:722-729.
36. Wilson E.H., Wille-Reece U., Dzierszinski F., Hunter C.A. A critical role for IL-10 in limiting inflammation during toxoplasmic encephalitis. J Neuroimmunol 2005, 165:63-74.
37. Redford P.S., Murray P.J., O'Garra A. The role of IL-10 in immune regulation during M. tuberculosis infection. Mucosal Immunol 2011, 4:261-270.
38. Loebbermann J., Schnoeller C., Thornton H., Durant L., Sweeney N.P., Schuijs M., et al. IL-10 regulates viral lung immunopathology during acute respiratory syncytial virus infection in mice. PLoS One 2012, 7:e32371.
39. Serhan C.N., Brain S.D., Buckley C.D., Gilroy D.W., Haslett C., O'Neill L.A., et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007, 21:325-332.
40. Sudo N., Sawamura S., Tanaka K., Aiba Y., Kubo C., Koga Y. The requirement of intestinal bacterial flora for the development of an IgE production system fully susceptible to oral tolerance induction. J Immunol 1997, 159:1739-1745.
41. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007, 449:819-826.
42. Kawai T., Akira S. Pathogen recognition with Toll-like receptors. Curr Opin Immunol 2005, 17:338-344.
43. Medzhitov R. TLR-mediated innate immune recognition. Semin Immunol 2007, 19:1-2.
44. Fitzgerald K.A., Palsson-McDermott E.M., Bowie A.G., Jefferies C.A., Mansell A.S., Brady G., et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 2001, 413:78-83.
45. Verstak B., Nagpal K., Bottomley S.P., Golenbock D.T., Hertzog P.J., Mansell A. MyD88 adapter-like (Mal)/TIRAP interaction with TRAF6 is critical for TLR2- and TLR4-mediated NF-kappaB proinflammatory responses. J Biol Chem 2009, 284:24192-24203.
46. Mancuso P., Canetti C., Gottschalk A., Tithof P.K., Peters-Golden M. Leptin augments alveolar macrophage leukotriene synthesis by increasing phospholipase activity and enhancing group IVC iPLA2 (cPLA2gamma) protein expression. Am J Physiol Lung Cell Mol Physiol 2004, 287:L497-L502.
47. Eddens T., Kolls J.K. Host defenses against bacterial lower respiratory tract infection. Curr Opin Immunol 2012, 24:424-430.
48. Clarke T.B. Early innate immunity to bacterial infection in the lung is regulated systemically by the commensal microbiota via nod-like receptor ligands. Infect Immun 2014, 82:4596-4606.
49. Jones R.M., Luo L., Ardita C.S., Richardson A.N., Kwon Y.M., Mercante J.W., et al. Symbiotic lactobacilli stimulate gut epithelial proliferation via Nox-mediated generation of reactive oxygen species. EMBO J 2013, 32:3017-3028.
50. Neish A.S., Jones R.M. Redox signaling mediates symbiosis between the gut microbiota and the intestine. Gut Microbes 2014, 5:250-253.
51. Molloy M.J., Bouladoux N., Belkaid Y. Intestinal microbiota: shaping local and systemic immune responses. Semin Immunol 2012, 24:58-66.